{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T09:46:59Z","timestamp":1791712019809,"version":"4.3.4"},"reference-count":35,"publisher":"Rambam Health Corporation","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rambam Maimonides Med J"],"DOI":"10.5041\/rmmj.10173","type":"journal-article","created":{"date-parts":[[2014,10,29]],"date-time":"2014-10-29T05:23:19Z","timestamp":1414560199000},"page":"e0039","source":"Crossref","is-referenced-by-count":24,"title":["Hemorrhagic Aspects of Gaucher Disease"],"prefix":"10.5041","volume":"5","author":[{"given":"Hanna","family":"Rosenbaum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2983","published-online":{"date-parts":[[2014,10,29]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. Grabowski GA. Gaucher disease. Enzymology, genetics, and treatment. Adv Hum Genet 1993; 21:377-441.","DOI":"10.1007\/978-1-4615-3010-7_5"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1182\/blood.V34.3.331.331","article-title":"The morphogenesis of Gaucher cells investigated by electron microscopy","volume":"34","author":"Pennelli","year":"1969","unstructured":"2. Pennelli N, Scaravilli F, Zacchello F. The morphogenesis of Gaucher cells investigated by electron microscopy. Blood 1969;34:331-47.","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S0950-3536(97)80037-6","article-title":"Pathological features","volume":"10","author":"GM. Gaucher's Disease","year":"1997","unstructured":"3. Pastores GM. Gaucher's Disease. Pathological features. Baillieres Clin Haematol 1997;10:739-49.","journal-title":"Baillieres Clin Haematol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/MOH.0b013e32835a9148","article-title":"Haematological manifestations and complications of Gaucher disease","volume":"20","author":"DA","year":"2013","unstructured":"4. Hughes DA, Pastores GM. Haematological manifestations and complications of Gaucher disease. Curr Opin Hematol 2013;20:41-7.","journal-title":"Curr Opin Hematol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/(SICI)1098-1004(1998)12:4<240::AID-HUMU4>3.0.CO;2-J","article-title":"Prevalence of glucocerebrosidase mutations in the Israeli Ashkenazi Jewish population","volume":"12","author":"Horowitz","year":"1998","unstructured":"5. Horowitz M, Pasmanik-Chor M, Borochowitz Z, et al. Prevalence of glucocerebrosidase mutations in the Israeli Ashkenazi Jewish population. Hum Mutat 1998;12:240-4.","journal-title":"Hum Mutat"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Elstein D, Zimran A. Using the International Gaucher Disease Registry data: can we devise a virtuous circle for treated patients? Am J Hematol 2008;83:887-9.","DOI":"10.1002\/ajh.21306"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Elstein D, Zimran A. Review of the safety and efficacy of imiglucerase treatment of Gaucher disease. Biologics 2009;3:407-17.","DOI":"10.2147\/BTT.2009.3497"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Aviezer D, Brill-Almon E, Shaaltiel Y, et al. A plant-derived recombinant human glucocerebrosidase enzyme--a preclinical and phase I investigation. PLoS One 2009;4:e4792.","DOI":"10.1371\/journal.pone.0004792"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ymgme.2014.02.011","article-title":"Taliglucerase alfa: an enzyme replacement therapy using plant cell expression technology","volume":"112","author":"Grabowski","year":"2014","unstructured":"9. Grabowski GA, Golembo M, Shaaltiel Y. Taliglucerase alfa: an enzyme replacement therapy using plant cell expression technology. Mol Genet Metab 2014;112:1-8.","journal-title":"Mol Genet Metab"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/S0002-9343(02)01150-6","article-title":"Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry","volume":"113","author":"Weinreb","year":"2002","unstructured":"10. Weinreb NJ, Charrow J, Andersson HC, et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 2002;113:112-19.","journal-title":"Am J Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/j.1399-0004.2007.00769.x","article-title":"The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease","volume":"71","author":"Charrow","year":"2007","unstructured":"11. Charrow J, Dulisse B, Grabowski GA, Weinreb NJ. The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease. Clin Genet 2007;71:205-11.","journal-title":"Clin Genet"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1023\/A:1025902113005","article-title":"The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement","volume":"26","author":"Cox","year":"2003","unstructured":"12. Cox TM, Aerts JM, Andria G, et al. The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J Inherit Metab Dis 2003;26:513-26.","journal-title":"J Inherit Metab Dis"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/00005792-199211000-00002","article-title":"Clinical, laboratory, radiologic, and genetic features of 53 patients","volume":"71","author":"Zimran","year":"1992","unstructured":"13. Zimran A, Kay A, Gelbart T, et al. Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients. Medicine (Baltimore) 1992;71:337-53.","journal-title":"Medicine (Baltimore)"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s10545-006-0377-x","article-title":"Iliopsoas haematoma in Gaucher disease","volume":"29","author":"Lesic","year":"2006","unstructured":"14. Lesic A, Suvajdzic N, Elezovic I, et al. Iliopsoas haematoma in Gaucher disease. J Inherit Metab Dis 2006;29:593.","journal-title":"J Inherit Metab Dis"},{"key":"ref14","unstructured":"15. Jmoudiak M, Itzchaki M, Hadas-Halpern I, et al. Iliopsoas hematoma in a young patient with type I Gaucher disease. Isr Med Assoc J 2003;5:673-4."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/j.1365-2141.2011.08613.x","article-title":"Platelet adhesion defect in type I Gaucher disease is associated with a risk of mucosal bleeding","volume":"153","author":"Spectre","year":"2011","unstructured":"16. Spectre G, Roth B, Ronen G, et al. Platelet adhesion defect in type I Gaucher disease is associated with a risk of mucosal bleeding. Br J Haematol 2011;153:372-8.","journal-title":"Br J Haematol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1046\/j.1365-2141.1997.d01-2076.x","article-title":"Coagulation abnormalities in type 1 Gaucher disease are due to low-grade activation and can be partly restored by enzyme supplementation therapy","volume":"96","author":"Hollak","year":"1997","unstructured":"17. Hollak CE, Levi M, Berends F, et al. Coagulation abnormalities in type 1 Gaucher disease are due to low-grade activation and can be partly restored by enzyme supplementation therapy. Br J Haematol 1997;96:470-6.","journal-title":"Br J Haematol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3109\/09537104.2011.597526","article-title":"Haemostatic abnormalities in treatment-naive patients with Type 1 Gaucher's disease","volume":"23","author":"Mitrovic","year":"2012","unstructured":"18. Mitrovic M, Antic D, Elezovic I, et al. Haemostatic abnormalities in treatment-naive patients with Type 1 Gaucher's disease. Platelets 2012;23:143-9.","journal-title":"Platelets"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19. Flipo RM, Adenis-Lavignasse C, Cortet B, et al. [\"Spontaneous\" hematoma of the psoas in Gaucher's disease]. Rev Med Interne 1992;13:293-5. [Article in French]","DOI":"10.1016\/S0248-8663(05)80304-2"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s10545-010-9175-6","article-title":"Focal splenic lesions in type I Gaucher disease are associated with poor platelet and splenic response to macrophage-targeted enzyme replacement therapy","volume":"33","author":"Stein","year":"2010","unstructured":"20. Stein P, Malhotra A, Haims A, et al. Focal splenic lesions in type I Gaucher disease are associated with poor platelet and splenic response to macrophage-targeted enzyme replacement therapy. J Inherit Metab Dis 2010;33:769-74.","journal-title":"J Inherit Metab Dis"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/0002-9343(84)90124-4","article-title":"Immune thrombocytopenia and Gaucher's disease","volume":"77","author":"Lester","year":"1984","unstructured":"21. Lester TJ, Grabowski GA, Goldblatt J, et al. Immune thrombocytopenia and Gaucher's disease. Am J Med 1984;77:569-71.","journal-title":"Am J Med"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22. Rosenbaum H, Napso T, Bonstein L. Immune thrombocytopenia in type I Gaucher disease. Blood 2007;110:3200a.","DOI":"10.1182\/blood.V110.11.3200.3200"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1365-2516.2011.02540.x","article-title":"Thrombocytopenia and bleeding in dental procedures of patients with Gaucher disease","volume":"18","author":"Givol","year":"2012","unstructured":"23. Givol N, Goldstein G, Peleg O, et al. Thrombocytopenia and bleeding in dental procedures of patients with Gaucher disease. Haemophilia 2012;18:117-21.","journal-title":"Haemophilia"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1080\/10245330500067181","article-title":"Survey of hematological aspects of Gaucher disease","volume":"10","author":"Zimran","year":"2005","unstructured":"24. Zimran A, Altarescu G, Rudensky B, et al. Survey of hematological aspects of Gaucher disease. Hematology 2005;10:151-6.","journal-title":"Hematology"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25. Pastores GM, Weinreb NJ, Aerts H, et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 2004;41(4 Suppl 5):4-14.","DOI":"10.1053\/j.seminhematol.2004.07.009"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s10545-008-0779-z","article-title":"Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring","volume":"31","author":"Cox","year":"2008","unstructured":"26. Cox TM, Aerts JM, Belmatoug N, et al. Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring. J Inherit Metab Dis 2008;31:319-36.","journal-title":"J Inherit Metab Dis"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1136\/jcp.47.2.162","article-title":"Acquired pseudo-pseudo Bernard-Soulier syndrome complicating Gaucher's disease","volume":"47","author":"Kelsey","year":"1994","unstructured":"27. Kelsey H, Christopoulos C, Gray AA, Machin SJ. Acquired pseudo-pseudo Bernard-Soulier syndrome complicating Gaucher's disease. J Clin Pathol 1994;47:162-5.","journal-title":"J Clin Pathol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/j.1399-0004.1982.tb01445.x","article-title":"Increased cerebroside concentration in plasma and erythrocytes in Gaucher disease: significant differences between type I and type III","volume":"22","author":"Nilsson","year":"1982","unstructured":"28. Nilsson O, Hakansson G, Dreborg S, et al. Increased cerebroside concentration in plasma and erythrocytes in Gaucher disease: significant differences between type I and type III. Clin Genet 1982;22:274-9.","journal-title":"Clin Genet"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/S0950-3536(97)80034-0","article-title":"Plasma and metabolic abnormalities in Gaucher's disease","volume":"10","author":"JM","year":"1997","unstructured":"29. Aerts JM, Hollak CE. Plasma and metabolic abnormalities in Gaucher's disease. Baillieres Clin Haematol 1997;10:691-709.","journal-title":"Baillieres Clin Haematol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1111\/j.1538-7836.2006.02037.x","article-title":"Platelet function and coagulation abnormalities in type 1 Gaucher disease patients: effects of enzyme replacement therapy (ERT)","volume":"4","author":"Giona","year":"2006","unstructured":"30. Giona F, Palumbo G, Amendola A, et al. Platelet function and coagulation abnormalities in type 1 Gaucher disease patients: effects of enzyme replacement therapy (ERT). J Thromb Haemost 2006;4: 1831-3.","journal-title":"J Thromb Haemost"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/(SICI)1096-8652(199906)61:2<103::AID-AJH5>3.0.CO;2-V","article-title":"Platelet function abnormalities in Gaucher disease patients","volume":"61","author":"Gillis","year":"1999","unstructured":"31. Gillis S, Hyam E, Abrahamov A, et al. Platelet function abnormalities in Gaucher disease patients. Am J Hematol 1999;61:103-6.","journal-title":"Am J Hematol"},{"key":"ref31","unstructured":"32. Seligsohn U, Zitman D, Many A, Klibansky C. Coexistence of factor XI (plasma thromboplastin antecedent) deficiency and Gaucher's disease. Isr J Med Sci 1976;12:1448-52."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/ajh.2830400215","article-title":"High incidence of factor XI deficiency in Gaucher's disease","volume":"40","author":"Berrebi","year":"1992","unstructured":"33. Berrebi A, Malnick SD, Vorst EJ, Stein D. High incidence of factor XI deficiency in Gaucher's disease. Am J Hematol 1992;40:153.","journal-title":"Am J Hematol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1080\/08880010701360619","article-title":"Acquired von Willebrand disease in a Turkish boy with Gaucher disease","volume":"24","author":"Tavil","year":"2007","unstructured":"34. Tavil B, Balci YI, Karacan C, et al. Acquired von Willebrand disease in a Turkish boy with Gaucher disease. Pediatr Hematol Oncol 2007;24:317-19.","journal-title":"Pediatr Hematol Oncol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/j.0954-6820.1974.tb08164.x","article-title":"Splenomegaly associated with chronic consumption coagulopathy","volume":"195","author":"Gerrits","year":"1974","unstructured":"35. Gerrits WB, van Aken WG, van der Meer J, Vreeken J. Splenomegaly associated with chronic consumption coagulopathy. Acta Med Scand 1974;195:425-30.","journal-title":"Acta Med Scand"}],"container-title":["Rambam Maimonides Medical Journal"],"original-title":[],"link":[{"URL":"https:\/\/www.rmmj.org.il\/userimages\/423\/1\/PublishFiles\/451Article.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T09:04:56Z","timestamp":1791709496000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.rmmj.org.il\/issues\/23\/Articles\/451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,29]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2014,10,29]]}},"URL":"https:\/\/doi.org\/10.5041\/rmmj.10173","relation":{},"ISSN":["2076-9172"],"issn-type":[{"value":"2076-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,29]]}}}